Sepiapterin reductase (SR) deficiency was recently described in patients with a severe biogenic amine deficiency presenting without hyperphenylalaninemia and it was suggested that the tetrahydrobiopterin ( 
Tetrahydrobiopterin (BH 4 ) deficiency is a rare form of hyperphenylalaninemia caused by autosomal recessive mutations in the genes encoding for the enzymes involved in the biosynthesis or regeneration of BH 4 (1) . BH 4 acts as a cofactor for phenylalanine, tyrosine, and tryptophan hydroxylases (2) and any defect in its metabolism affects both phenylalanine and biogenic amine neurotransmitter homeostasis. Furthermore, BH 4 is essential for the production of the nitric oxide (NO) free radical by all the isoforms of NO synthase, and patients with BH 4 deficiency have reduced production of NO in the brain (3) . Patients with BH 4 deficiencies present with mental retardation, convulsions (grand mal or myoclonic attacks), disturbance of tone and posture, oculogyric crises, drowsiness, irritability, abnormal movements, recurrent hyperthermia without infections, hypersalivation, and swallowing difficulties. Two forms of BH 4 deficiency present without hyperphenylalaninemia: Dopa-responsive dystonia due to autosomal dominant mutations in the GTP cyclohydrolase I gene and the recently discovered sepiapterin reductase (SR) deficiency (4, 5) . In contrast to classical forms of BH 4 deficiencies which can be detected via the newborn screening for phenylketonuria (PKU) these disorders can be diagnosed only by CSF investigations of dopamine and serotonin metabolites (5-hydroxyindoleacetic acid and homovanillic acid) and pterins (neopterin and biopterin) (6). More accurate diagnosis is possible by the measurement of neopterin and biopterin in cytokine-stimulated fibroblasts or by the enzyme activity measurement in stimulated cells for the GTP cyclohydrolase I and in the nonstimulated cells for SR (7) .
Diagnosis of SR deficiency is not simple due to a) the absence of hyperphenylalaninemia and b) the fact that the pterins profile in CSF is the same as in patients with defective dihydropteridine reductase (high dihydrobiopterin and biopterin). However, because in SR patients dihydropteridine reductase activity is normal, dihydrobiopterin probably originates from sepiapterin formed in the salvage pathway. The two-step reduction of the intermediate 6-pyruvoyltetrahydropterin to BH 4 can be catalyzed by two additional reductases, carbonyl and aldose reductase. We developed a new approach for the rapid diagnosis of SR deficiency by measurement of sepiapterin in CSF.
PATIENTS AND METHODS

Patients.
Patients with the SR deficiency are registered in the international BIODEF database (www.bh4.org/biodef1.html). Diagnosis was established by the measurement of pterins and SR activity in cytokine-stimulated and in nonstimulated cultured skin fibroblasts, respectively, as published previously (5) . Initial analysis of CSF revealed high dihydrobiopterin and biopterin concentrations and a severe biogenic amine neurotransmitter deficiency (8) . The procedures used were in accordance with the current revision of the Helsinki Declaration of 1975. Appropriate informed consents were obtained from all subjects.
Chemicals. Pterins (xanthopterin, sepiapterin, 3-hydroxysepiapterin) were obtained from Dr. Schircks Laboratories (Jona, Switzerland) and SepPak C18 cartridges were from Waters Associates (Milford, MA).
Sample concentration on the Sep-Pak C18. Sepiapterin and its analogue are very sensitive to light and oxygen. When not protected both pterins were oxidized to a nonfluorescent 7,8-dehydro compound (6-lactylpterins). Therefore, samples and standard solutions should be kept in dark vials at Ϫ20°C. Prior to use cartridges were activated with 2 ml of methanol and 10 ml of water as previously described by Ferre and Jackobson (9) . Then, 0.5 ml of fresh CSF (stored at Ϫ20°C protected from light) was applied, and the column was washed with 3 ml of water and eluted with 1.5 ml of methanol. The methanol fraction was evaporated in a Speed Vac Concentrator SVC-100H (Savant Instruments, Formingdale, NY) for 3-4 h protected from light. The residue was dissolved in 100 l of water (degassed with nitrogen) and used for the HPLC of pterins. 
RESULTS
CSF analysis.
Chromatograms of a standard mixture and CSF from a control person and the patient with SR deficiency are shown in Fig. 1 . Normal CSF contains no xanthopterin, 3Ј-hydroxysepiapterin, or sepiapterin (Ͻ0.5 nmol/L). In contrast, in CSF from two patients with SR deficiency, sepiapterin was significantly increased (5.6 and 11.4 nmol/ L). There was no 3Ј-hydroxysepiapterin and only traces of xanthopterin were detectable. We also investigated two CSF samples from patients with 6-pyruvoyltetrahydropterin synthase deficiency; however, we found no 3Ј-hydroxysepiapterin (data not shown). In contrast to the patient investigated by Niederwieser et al., (10) , our patients were already on treatment with BH 4 .
Urine analysis. HPLC of yellow fluorescing pterins revealed numerous unknown peaks in both control urines and samples from patients with SR deficiency; however, there was no sepiapterin detectable (data not shown). Using the same system with the longer run time urinary riboflavin can be measured (RT, 25 min).
DISCUSSION
SR deficiency is a recently recognized form of BH 4 deficiency (5, 11) . Affected patients present with severe dopamine and serotonin deficiency without hyperphenylalaninemia and thus cannot be detected by the newborn screening for PKU. So far, three patients have been detected and in all of them initial investigations of CSF pterins revealed high concentrations of dihydrobiopterin and biopterin (6) . Using the new assay with cytokine-stimulated fibroblasts (7) and the DNA analysis (5), final diagnosis was established. It has been suggested that in patients with SR deficiency, peripheral BH 4 biosynthesis proceeds via the route catalyzed by carbonyl, aldose, and dihydrofolate reductases (5) and that in the brain 7,8-dihydrobiopterin cannot be converted to BH 4 due to the low dihydrofolate reductase activity. To test the hypothesis that in patients with SR deficiency brain 7,8-dihydrobiopterin originates from sepiapterin we investigated their CSF using a new HPLC system for yellow fluorescing pterins. This was confirmed by increased levels of sepiapterin, but not xanthopterin and 3Ј-hydroxysepiapterin in both patients. Sepiapterin was not detectable in CSF from patients with dihydropteridine reductase deficiency, another form of BH 4 deficiency presenting with high 7,8-dihydrobiopterin in the brain (12) . In contrast to the brain enzyme, peripheral dihydrofolate reductase may efficiently reduce 7,8-dihydrobiopterin to BH 4 and thus maintain hydroxylation of phenylalanine in the liver. The amount of BH 4 produced in peripheral tissue is sufficient to prevent hyperphenylalaninemia. We were also not able to detect any sepiapterin in urine of patients with SR deficiency.
The HPLC method we described is simple and fast and can detect as little as 1 nmol/L of sepiapterin. Measurement of sepiapterin in CSF may not only be important for the rapid diagnosis of SR deficiency but may also contribute to the elucidation of the negative effect of sepiapterin and positive effect of BH 4 on the neuronal NOS (13) . Recently, it has been shown that not only 7,8-dihydrobiopterin but also sepiapterin can uncouple the NOS reaction by releasing the prebound BH 4 (14) and that under BH 4 -deficient conditions consumption of NADPH can become uncoupled from NO synthesis, resulting in the production of superoxide anions and peroxynitrite (15) . We proposed recently that in patients with SR and dihydropteridine reductase deficiency uncoupling of the NOS reaction may lead to neuronal cell dysfunction (6, 11) . This event may potentate neurological abnormalities caused by dopamine and serotonin depletion in these patients.
